Early phase clinical trials in pediatric hematology and oncology

Klinische Padiatrie

Volumn 224, Issue 3, 2012, Pages 197-200

  Corbacioglu, S ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

children; pediatric oncoclogy; phase 1 clinical trials; phase 2 clinical trials

Indexed keywords

ARTICLE; CHILDHOOD CANCER; DRUG INDUSTRY; EVIDENCE BASED MEDICINE; HEMATOLOGIC DISEASE; HUMAN; MEDICAL SOCIETY; ORGANIZATIONAL DEVELOPMENT; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICIAN ATTITUDE; PROFESSIONAL COMPETENCE; PROFESSIONAL KNOWLEDGE; PUBLIC-PRIVATE PARTNERSHIP; RISK ASSESSMENT; RISK FACTOR; TREATMENT PLANNING;

ACADEMIC MEDICAL CENTERS; ANTINEOPLASTIC AGENTS; CHILD; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; COOPERATIVE BEHAVIOR; COST-BENEFIT ANALYSIS; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; EUROPE; FORECASTING; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INDIVIDUALIZED MEDICINE; INTERDISCIPLINARY COMMUNICATION; LEUKEMIA; MOLECULAR TARGETED THERAPY; NATIONAL HEALTH PROGRAMS; NEOPLASMS; PROSPECTIVE STUDIES;

EID: 84860598168     PISSN: 03008630     EISSN: 14393824     Source Type: Journal    
DOI: 10.1055/s-0032-1308986     Document Type: Article

References (33)

1. Ablett S, Doz F, Morland B et al. European collaboration in trials of new agents for children with cancer. Eur J Cancer: 2004; 40 1886 1892 (Pubitemid 39036764)
2. Bergmann L, Berns B, Dalgleish A G et al. Investigator-initiated trials of targeted oncology agents: why independent research is at risk? Ann Oncol: 2010; 21 1573 1578
3. Bleyer W A. The impact of childhood cancer on the United States and the world. Cancer J Clin: 1990; 40 355 367
4. Boklan J. Little patients, losing patience: pediatric cancer drug development. Mol Cancer Ther: 2006; 5 1905 1908 (Pubitemid 44336560)
5. Brecht I B, Graf N, Schweinitz D et al. Networking for children and adolescents with very rare tumors: foundation of the GPOH Pediatric Rare Tumor Group. Klin Padtr: 2009; 221 181 185
6. Brenner H, Kaatsch P, Burkhardt-Hammer T et al. Long-term survival of children with leukemia achieved by the end of the second millennium. Cancer: 2001; 92 1977 1983 (Pubitemid 32952519)
7. Bucheler R, Meisner C, Kalchthaler B et al. "Off-labelo" prescribing of drugs in the ambulatory care of children and adolescents. Deut Med Wochenschr: 2002; 127 2551 2557
8. Caldwell P H, Murphy S B, Butow P N et al. Clinical trials in children. Lancet: 2004; 364 803 811 (Pubitemid 39165102)
9. Choonara I. Unlicensed and off-label drug use in children: implications for safety. Expert Opin Drug Saf: 2004; 3 81 83 (Pubitemid 38765189)
10. Conroy S, McIntyre J, Choonara I. Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonatal Ed: 1999; 80 F142 F144 discussion F144-F145
11. Corbacioglu S, Cesaro S, Faraci M et al. A randomised controlled trial of defibrotide for the prophylaxis of hepatic veno-occlusive disease in paediatric stem-cell transplantation. Lancet: 2012; doi:10.1016/S0140-6736(11)61938-7
12. DiMasi J A, Hansen R W, Grabowski H G. The price of innovation: new estimates of drug development costs. J Health Econ: 2003; 22 151 185 (Pubitemid 36279392)
13. Druker B J, Talpaz M, Resta D J et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. NEJM: 2001; 344 1031 1037 (Pubitemid 32267972)
14. Geoerger B, Vassal G. Innovative Therapies for Children with Cancer (ITCC): Clinical trial programm. Klin Padiatr: 2011; 223 50 10.1055/s-0030- 1270318
15. Gulland A. Number of global clinical trials done in UK fell by two thirds after EU directive. BMJ: 2009; 338 b1052
16. Houghton P J. Development of Novel Therapy for Childhood Cancer: Promise and challenges. Klin Padiatr: 2011; 223 50 10.1055/s-0030-1270316
17. Jordan V C, Koerner S. Tamoxifen (ICI 46 474) and the human carcinoma 8 S oestrogen receptor. Eur J Cancer: 1975; 11 205 206
18. Murphy S B. The national impact of clinical cooperative group trials for pediatric cancer. Med Pediatr Oncol: 1995; 24 279 280
19. Nathan P C, Ness K K, Mahoney M C et al. Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: a report from the childhood cancer survivor study. Ann Intern Med: 2010; 153 442 451
20. Neubert A, Dormann H, Weiss J et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf: 2004; 27 1059 1067 (Pubitemid 39487067)
21. Oeffinger K C, Mertens A C, Sklar C A et al. Chronic health conditions in adult survivors of childhood cancer. NEJM: 2006; 355 1572 1582 (Pubitemid 44547808)
22. Pharmaceutical Industry Profile 2004 In: Pharmaceutical Research and Manufacturers of America (PhRMA). ed PhRMA Washington DC: 2004; 2004
23. Sammons H. Ethical issues of clinical trials in children: a European perspective. Arch Dis Child: 2009; 94 474 477
24. Sammons H. Ethical issues of clinical trials in children: a European perspective. Arch Dis Child: 2009; 94 474 477
25. Schneider D T, Brecht I B. Care for rare cancers: improved care requires improved communication. Klin Padtr: 2010; 222 124 126
26. Shirkey H. Therapeutic orphans. J Pediatr: 1968; 72 119 120
27. Shiroiwa T, Motoo Y, Tsutani K. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. Mol Diagn Ther: 2010; 14 375 384
28. Simone J V, Lyons J. The evolution of cancer care for children and adults. J Clin Oncol: 1998; 16 2904 2905 (Pubitemid 28417407)
29. Sinha G. European move affects academic trials research. J Natl Cancer Inst: 2006; 98 1100 1101
30. Slamon D J, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEJM: 2001; 344 783 792 (Pubitemid 32222155)
31. Sullivan R, Peppercorn J, Sikora K et al. Delivering affordable cancer care in high-income countries. Lancet Oncol: 2011; 12 933 980
32. Turner S, Longworth A, Nunn A J et al. Unlicensed and off label drug use in paediatric wards: prospective study. BMJ: 1998; 316 343 345 (Pubitemid 28121257)
33. Turner S, Nunn A J, Fielding K et al. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr: 1999; 88 965 968 (Pubitemid 29448261)